US EditionStudies Offer Conflicting Evidence on Beta-Blocker Benefits After Heart Attacks
The REBOOT trial found beta-blockers do not improve outcomes in patients with normal heart function and increase death risk by 2.7% in women, indicating need for sex-specific treatment guidelines.
- A major clinical trial showed that women treated with beta-blockers after a heart attack had a higher risk of death, reinfarction, or hospitalization for heart failure compared to women not receiving the drug.
- While men experienced no benefit or risk when treated with beta-blockers, women with normal cardiac function after a heart attack who received beta-blockers had a 2.7% higher absolute risk of mortality than those not treated with beta-blockers over 3.7 years.
- Women presenting with heart attacks tended to have a worse cardiovascular profile, including being older, having more comorbidities, and more frequently experiencing heart attacks without obstructive coronary arteries compared to men.
36 Articles
36 Articles
Common heart drug taken by millions found useless, possibly risky
Beta blockers, used for decades after heart attacks, provide no benefit for patients with preserved heart function, according to the REBOOT trial. The massive study also found women faced higher risks when taking the drug. Experts say the results will change heart treatment guidelines worldwide.
According to a new research reported by CNN, a class of medicines called beta-blockers, used for decades as a first-line treatment after a heart attack, does not benefit the vast majority of patients.
By Sandee LaMotte, CNN A class of drugs called beta-blockers, used for decades as a first-line treatment after a heart attack, does not benefit the vast majority of patients and could contribute to an increased risk of hospitalization and death in some women, although not in men, according to a new research. “These findings will redefine all international clinical guidelines on the use of beta-blockers in men and women, and should promote a long…
By Sandee LaMotte, CNN A class of drugs called beta-blockers, used for decades as a first-line treatment after a heart attack, does not benefit the vast majority of patients and could contribute to an increased risk of hospitalization and death in some women, although not in men, according to a new research. “These findings will redefine all international clinical guidelines on the use of beta-blockers in men and women, and should promote a long…
The international clinical trial 'Reboot' has shown that beta-blockers, drugs that have been prescribed for 40 years after a myocardial infarction, not only do not provide any benefit to patients with uncomplicated infarctions, but also raise the risk of death or reinfarction in women. 'Reboot', coordinated by the CNIC in collaboration with the Mario Negri Institute in Milan (Italy), was launched five years ago to determine whether prescribed li…
Colorado Springs Gazette
Does a common heart attack pill help everyone? Studies disagree
By Nancy Lapid
Coverage Details
Bias Distribution
- 87% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
